Metformin: an important tool for endocrinology in the West Indies. New tricks for an old drug

Abstract

Against the backdrop of an obesity pandemic, comes an increasing prevalence of metabolic (e.g. type 2 diabetes mellitus) and reproductive abnormalities (e.g. polycystic ovarian syndrome) mediated by the phenomenon of insulin resistance. Metformin is an inexpensive and widely available drug which partly through an insulin sensitising action has an antidiabetic action with unique cardioprotective effects and which has value in preventing progression of pre-diabetes to diabetes. Despite mounting favourable data its role in polycystic ovarian syndrome remains unsettled. The recent finding for its safety and efficacy in gestational diabetes, however, will no doubt lift concerns over its use in women in the reproductive age group. One immediate result would be its earlier and greater therapeutic application in under-resourced environments where cost and emotional barriers to insulin exist.

Keywords

gestational diabetes insulin resistance syndrome metformin polycystic ovarian syndrome pregnancy reproductive age West Indies

Get full access to this article

View all access options for this article.

References

Poon-King T. , Henry MU , Rampersad F. Prevalence and natural history of diabetes in Trinidad. Lancet 1969 ;i:155-60.

Miller GJ , Beckles GL , Maude GH et al. Ethnicity and other characteristics predictive of coronary heart disease in a developing community: principal results of the St James Survey, Trinidad. Int J Epidemiol 1989;18:808-17.

Fraser HS , Forrester T. , Wilks R. The obesity epidemic of the Caribbean. West Indian Med J 1996;45:1-2.

Wilks R. , Bennett F. , Forrester T. , McFarlane-Anderson N. Chronic diseases: the new epidemic. West Indian Med J 1998;47(suppl 4):40-4.

Verghese A.

‘Between Father and Son: Family Letters’

The New York Times January 16 2006, http://www.nytimes.com/books/00/01/16/reviews/000116.16verghet.html. Last accessed 21 July 2009.

Wattley GH Heart disease in Trinidad. West Indian Med J 1960;9:189-93.

Barceló A. Cardiovascular diseases in Latin America and the Caribbean. Lancet 2006;368:625-6.

Forrester T. , Wilks R. , Bennett F. et al. Obesity in the Caribbean. Ciba Found Symp 1996;201:17-26

Bonora E. The metabolic syndrome and cardiovascular disease. Ann Med 2006;38:64-80.

10.

Larrañaga I. , Arteagoitia JM , Rodriguez JL et al. The Sentinel Practice Network of the Basque Country. Socio-economic inequalities in the prevalence of Type 2 diabetes, cardiovascular risk factors and chronic diabetic complications in the Basque Country, Spain. Diabet Med 2005;22:1047-53.

11.

Wilder R. , Majumdar S. , Klarenbach S. , Jacobs P. Socio-economic status and undiagnosed diabetes. Diabet Res Clin Pract 2005;70:26-30.

12.

Bailey CJ , Campbell IW , Chan JCN et al. (eds). Metformin. The Gold Standard. Chichester : John Wiley & Sons Ltd, 2007 ;288.

13.

Swaby P. , Wilson E. , Swaby S. et al. Chronic diseases management in the Jamaican setting: HOPE worldwide Jamaica’s experience. P N G Med J 2001 ;44:171-5.

14.

Mahabir D. , Gulliford MC Changing patterns of primary care for diabetes in Trinidad and Tobago over 10 years. Diabet Med 2005;22:619-24.

15.

Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998;352:854-65.

16.

Marchesini G. , Brizi M. , Bianchi G. et al. Metformin in non-alcoholic steatohepatitis . Lancet 2001 ;358:893-4.

17.

Ibáñez L. , Ong K. , Valls C. et al. Metformin treatment to prevent early puberty in girls with precocious pubarche. J Clin Endocrinol Metab 2006;91:2888-91.

18.

Lord JM , Flight IHK , Norman RJ Metformin in polycystic ovary syndrome: systematic review and meta-analysis . BMJ 2003;327:951-3.

19.

Teelucksingh S. , El-Youssef J. , Sohan K. , Ramsewak S. Prolonged inadvertent pravastatin use in pregnancy . Reprod Toxicol 2004;18:299-300.

20.

Acosta I. , Aponte Z. , de- Jesús Z. et al. Prevalence of diabetes mellitus among pregnant women receiving health services at the Puerto Rico University Hospital, Puerto Rico, 1997-1998 . P R Health Sci J 2001;201:65-70.

21.

Irving RR , Mills JL , Choo-Kang EG et al. The burden of gestational diabetes mellitus in Jamaican women with a family history of autosomal dominant type 2 diabetes. Rev Panam Salud Publica 2008;23:85-91.

22.

Coetzee EJ Counterpoint: Oral hypoglyemic agents should be used to treat diabetic pregnant women. Diabetes Care 2007;30:2980-2.

23.

Rowan JA , Hague WM , Gao W. et al. MiG Trial Investigators. Metformin versus insulin for the treatment of gestational diabetes. N Engl J Med 2008 ;358:2003-15.

24.

Glueck CJ , Goldenberg N. , Pranikoff J. et al. Height, weight, and motor-social development during the first 18 months of life in 126 infants born to 109 mothers with polycystic ovary syndrome who conceived on and continued metformin through pregnancy. Hum Reprod 2004;19:1323-30.

25.

Glueck CJ , Wang P. Metformin before and during pregnancy and lactation in polycystic ovary syndrome . Expert Opin Drug Saf 2007 ;6:191-8.

26.

Lord JM , Flight IH , Norman RJ Insulin-sensitising drugs (metformin, troglitazone, rosiglitazone, pioglitazone, d-chiro-inositol) for polycystic ovary syndrome. Cochrane Database Syst Rev 2003;3:CD003053.

27.

Teede HJ , Meyer C. , Norman RJ Insulin-sensitisers in the treatment of polycystic ovary syndrome . Expert Opin Pharmacother 2005;6: 2419-27.

28.

Tan S. , Hahn S. , Benson S. et al. Metformin improves polycystic ovary syndrome symptoms irrespective of pre-treatment insulin resistance. Eur J Endocrinol 2007;157:669-76.

29.

Barbieri RL

Clomiphene versus metformin for ovulation induction in polycystic ovary syndrome: the winner is

J Clin Endocrinol Metab 2007;92:3399-401.

30.

Palomba S. , Orio F. Jr , Falbo A. et al. Prospective parallel randomized, double-blind, double-dummy controlled clinical trial comparing clomiphene citrate and metformin as the first-line treatment for ovulation induction in nonobese anovulatory women with polycystic ovary syndrome. J Clin Endocrinol Metab 2005 ;90:4068-74.

31.

Thessaloniki ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Consensus on infertility treatment related to polycystic ovary syndrome. Fertil Steril 2008;89:505-22.

32.

Polycystic Ovary Syndrome Writing Committee. American Association of Clinical Endocrinologists position statement on metabolic and cardiovascular consequences of polycystic ovary syndrome. American Association of Clinical Endocrinologists position statement on metabolic and cardiovascular consequences of polycystic ovary syndrome. Endocr Pract 2005;11:125-34.